Exploring High Growth Tech Stocks In The United States October 2024

In This Article:

In the last week, the United States market has stayed flat, yet it has risen by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving sector.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.86%

27.98%

★★★★★★

Sarepta Therapeutics

23.67%

43.81%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Ardelyx

27.19%

66.44%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Amicus Therapeutics

20.32%

62.45%

★★★★★★

AsiaFIN Holdings

60.53%

81.55%

★★★★★★

Travere Therapeutics

26.51%

69.33%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 252 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

ADMA Biologics

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.70 billion.

Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, contributing $326.70 million, and Plasma Collection Centers, adding $3.41 million. The company is involved in the production and sale of plasma-derived biologics aimed at addressing immune deficiencies and infectious diseases on a global scale.

ADMA Biologics, recently added to the S&P 600 and 1500 indices, is demonstrating robust growth with its latest earnings revealing a significant turnaround: a net income of $32.06 million from a loss last year and revised upward revenue projections for 2024 and 2025. This surge in performance is underpinned by an aggressive R&D strategy that allocates substantial resources towards innovation—critical in the biotech sector where development cycles are long but potentially lucrative. The company's commitment to R&D, marked by expenses aligning closely with industry demands for cutting-edge biologic treatments, positions it well for sustained growth amidst forecasts of revenue increasing at 14.8% annually and earnings expected to rise by approximately 26% per year.

NasdaqGM:ADMA Revenue and Expenses Breakdown as at Oct 2024
NasdaqGM:ADMA Revenue and Expenses Breakdown as at Oct 2024

DigitalOcean Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: DigitalOcean Holdings, Inc. operates a global cloud computing platform through its subsidiaries across North America, Europe, Asia, and other international markets with a market cap of approximately $3.84 billion.